Taiwan · Delayed Price · Currency is TWD Original BioMedicals Statistics
Total Valuation
TPEX:6483 has a market cap or net worth of TWD 881.87 million. The enterprise value is 820.26 million.
| Market Cap | 881.87M |
| Enterprise Value | 820.26M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6483 has 66.81 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 66.81M |
| Shares Outstanding | 66.81M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 14.92% |
| Owned by Institutions (%) | n/a |
| Float | 12.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.95 |
| P/TBV Ratio | 7.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.02, with a Debt / Equity ratio of 0.08.
| Current Ratio | 7.02 |
| Quick Ratio | 5.15 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -180.23 |
Financial Efficiency
Return on equity (ROE) is -63.64% and return on invested capital (ROIC) is -38.21%.
| Return on Equity (ROE) | -63.64% |
| Return on Assets (ROA) | -35.35% |
| Return on Invested Capital (ROIC) | -38.21% |
| Return on Capital Employed (ROCE) | -88.40% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -4.09M |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.22 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.46 |
| 200-Day Moving Average | 14.02 |
| Relative Strength Index (RSI) | 42.78 |
| Average Volume (20 Days) | 83,097 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -104.00M |
| Pretax Income | -102.24M |
| Net Income | -102.24M |
| EBITDA | -99.31M |
| EBIT | -104.00M |
| Earnings Per Share (EPS) | -1.53 |
Balance Sheet
The company has 70.77 million in cash and 9.16 million in debt, with a net cash position of 61.61 million or 0.92 per share.
| Cash & Cash Equivalents | 70.77M |
| Total Debt | 9.16M |
| Net Cash | 61.61M |
| Net Cash Per Share | 0.92 |
| Equity (Book Value) | 110.95M |
| Book Value Per Share | 1.66 |
| Working Capital | 99.49M |
Cash Flow
In the last 12 months, operating cash flow was -122.49 million and capital expenditures -3.11 million, giving a free cash flow of -125.60 million.
| Operating Cash Flow | -122.49M |
| Capital Expenditures | -3.11M |
| Depreciation & Amortization | 4.68M |
| Net Borrowing | -4.14M |
| Free Cash Flow | -125.60M |
| FCF Per Share | -1.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6483 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -11.59% |
| FCF Yield | -14.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TPEX:6483 has an Altman Z-Score of 15.49.
| Altman Z-Score | 15.49 |
| Piotroski F-Score | n/a |